$1,000 follows their calls into $1,117
All in the world market (VT). No called asset is counting right now.
BDigs@B__Digs$NBIS is a winner. Can't you see it? Too many FinTwit thesis, wasted words. Jensen has SCREAMED it to you. He knew Arkady before we knew him. If your smooth brain doesn't understand who Arkady is, I can't help you. Just focus, ask questions, model it, ask your favorite LLM,
BDigs@B__DigsArkady's $NBIS is worth more than 5-6x sales at this point in its growth curve. If you don't see this, I can't help you.
BDigs@B__DigsThis... Christian has been screaming 'buy me' for months. Then he took the best he could get for $ATAI which has a LONG way to go to prove it is marketable.
Biobio@FischerbioPerhaps it tells you, that the others did not want to get bought
BDigs@B__DigsIf you buy a green open on $NBIS you are going to get bagged so hard.
BDigs@B__DigsGreat post but TLDR summary is $CMPS comes out like roses and the 'they didn't need that depth of trial' gang is about to look sad. There is a lot in these developments which take the shine off $DFTX
Brandon Richard@BreakoutBiotech$ATAI $CMPS $DFTX So much exciting news for psychedelics. This latest federal rollout is a massive, coordinated effort to de-risk the psychedelic drug development pipeline, slash red tape, and prep the healthcare system for commercialization: 1. FDA FINAL GUIDANCE • The
